Dr. Voss on the Future of Clinical Trials for Kidney Cancer

Martin H. Voss, MD
Published: Tuesday, Dec 26, 2017



Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

According to Voss, collaboration is important for the neoadjuvant concepts that are being developed. It is important discuss systemic therapies in a surgical context and as a multidisciplinary effort.

The key to successful development of approaches is to have a multidisciplinary team involved, says Voss.
 
SELECTED
LANGUAGE


Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

According to Voss, collaboration is important for the neoadjuvant concepts that are being developed. It is important discuss systemic therapies in a surgical context and as a multidisciplinary effort.

The key to successful development of approaches is to have a multidisciplinary team involved, says Voss.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x